StockFacets
About
Sign-up
Sign-in
Earnings Calendar
Prices are updated after-hours
Published
Previous years
144
This year
14
Publishing Date
2024 - 02 - 23
2
2024 - 02 - 21
2
2024 - 02 - 16
2
2024 - 01 - 25
2
2023 - 11 - 27
2
2023 - 10 - 22
2
2023 - 10 - 18
2
2023 - 09 - 26
2
2023 - 09 - 25
2
2023 - 08 - 18
2
2023 - 06 - 27
2
2023 - 04 - 26
2
2023 - 03 - 28
2
2023 - 03 - 21
2
2023 - 03 - 07
2
2023 - 01 - 30
2
2023 - 01 - 27
2
2022 - 12 - 16
2
2022 - 12 - 15
2
2022 - 11 - 17
2
2022 - 09 - 28
2
2022 - 09 - 05
2
2022 - 06 - 24
2
2022 - 06 - 08
1
2022 - 06 - 07
2
2022 - 06 - 02
1
2022 - 05 - 31
2
2022 - 05 - 20
3
2022 - 04 - 14
1
2022 - 04 - 07
2
2022 - 04 - 04
2
2022 - 03 - 16
1
2022 - 02 - 28
2
2022 - 02 - 11
1
2022 - 02 - 10
1
2022 - 01 - 31
1
2022 - 01 - 19
2
2022 - 01 - 06
1
2021 - 10 - 22
1
2021 - 10 - 15
1
2021 - 10 - 14
1
2021 - 09 - 29
1
2021 - 09 - 28
1
2021 - 08 - 04
1
2021 - 08 - 03
1
2021 - 07 - 27
1
2021 - 07 - 20
1
2021 - 06 - 26
1
2021 - 06 - 25
4
2021 - 06 - 14
1
2021 - 06 - 11
1
2021 - 06 - 08
1
2021 - 06 - 04
1
2021 - 05 - 24
1
2021 - 04 - 01
1
2021 - 03 - 30
1
2021 - 03 - 18
2
2021 - 03 - 15
1
2021 - 03 - 04
1
2021 - 02 - 25
1
Sector
Communications
1
Consumer non-durables
1
Consumer services
1
Electronic technology
1
Energy minerals
1
Health care and social assistance
1
Health technology
144
Manufacturing
1
N/a
1
Non-energy minerals
1
Process industries
1
Producer manufacturing
1
Technology services
1
Utilities
1
Tags
Agreement
5
Alliances
4
Alzheimer’s
3
Antibody
3
Application
6
Approval
10
Approved
19
Biotech-bay
4
Cancer
14
Casirivimab
4
Cell
3
Children
26
Chmp
8
Cholesterol
3
Clinical-trials-phase-iii
3
Collaboration
9
Copd
4
Covid
4
Crispr
6
Dermatitis
7
Diabetic
4
Disease
13
Dupixent
45
Europe
5
Evkeeza
5
Eylea
5
Fda
46
Fda acceptance
5
Fda approval
3
First
4
Genetown
7
Global
3
Hypercholesterolemia
3
Immunotherapy
3
Injection
5
Innovation
3
Intel
3
Japan
3
Libtayo
7
License
4
Lung
3
Macular
5
N/a
99
Ntla-2001
6
Order
4
Pharm-country
8
Phase 1
6
Phase 3
6
Positive
13
Research
17
Results
8
Review
19
Six
5
Study
4
Therapeutics
6
Therapy
12
Treatment
48
Trial
8
Urticaria
5
Year
6
Entities
2seventy bio, inc.
1
Abbvie inc.
2
Adagio therapeutics inc
1
Alnylam pharmaceuticals, inc.
5
Alvotech lux holdings s.a.s.
1
Amgen inc.
2
Astrazeneca plc
2
Biogen inc.
1
Bristol-myers squibb company
1
Cytomx therapeutics, inc.
2
Decibel therapeutics inc
1
Eli lilly and company
2
Gilead sciences, inc.
1
Intellia therapeutics, inc.
11
Johnson & johnson
1
Kamada ltd.
1
Kering
1
Kiniksa pharmaceuticals, ltd.
3
Mks instruments, inc.
1
Moderna, inc.
1
Modivcare inc
1
Msci inc
1
Mueller industries, inc.
1
Netflix, inc.
1
Neurocrine biosciences, inc.
1
Newmont corporation
1
Novartis ag
1
Novavax, inc.
1
Novo nordisk a/s
1
Nrg energy, inc.
1
Nutanix, inc.
1
Nutrien ltd.
1
Oge energy corp
1
Olympic steel, inc.
1
Omnicell, inc.
1
Orange
1
Ovintiv inc.
1
Par pacific holdings, inc.
1
Paycom software, inc.
1
Paypal holdings, inc.
1
Pinterest, inc.
1
Qualcomm incorporated
1
Rayonier advanced materials inc.
1
Regeneron pharmaceuticals, inc.
144
Renewable energy group, inc.
1
Sanofi
102
Teva pharmaceutical industries ltd
35
Twist bioscience corporation
1
Ultragenyx pharmaceutical inc.
3
Xeris pharmaceuticals, inc.
1
Symbols
AAPL
192
ABB
220
ABBV
235
ABLZF
207
ABT
287
AMGN
116
ARVL
722
AZN
119
BDX
122
BMO
187
BMY
186
BNPQF
150
BNPQY
150
CM
121
CSCO
202
CSSE
134
DSX
131
DUK
116
ERIC
276
FE
109
FNCTF
1248
GE
151
GILD
110
GOOG
140
GOOGL
142
GSK
144
HON
254
HUBS
220
INCY
154
INTC
183
IT
381
JNJ
813
LLY
410
LTUM
142
MDT
246
MMM
156
MRK
143
MS
464
MSFT
189
NVDA
130
NVS
199
NVSEF
167
ORCL
204
PCRFF
112
PCRFY
112
PFE
201
PHG
118
PPRUF
170
PPRUY
170
REGN
144
RY
139
SAP
256
SAPGF
228
SNOW
117
SNY
904
SNYNF
744
TAK
122
TEVJF
152
TMO
267
VZ
203
Exchanges
Nasdaq
144
Nyse
4
Crawled Date
2024 - 02 - 23
2
2024 - 02 - 21
2
2024 - 02 - 16
2
2024 - 01 - 25
2
2023 - 11 - 27
2
2023 - 10 - 22
2
2023 - 10 - 18
2
2023 - 09 - 26
2
2023 - 09 - 25
2
2023 - 08 - 18
2
2023 - 06 - 27
2
2023 - 04 - 26
2
2023 - 03 - 28
2
2023 - 03 - 21
2
2023 - 03 - 07
2
2023 - 01 - 30
2
2023 - 01 - 27
2
2022 - 12 - 16
2
2022 - 12 - 15
2
2022 - 11 - 17
2
2022 - 09 - 28
2
2022 - 09 - 05
2
2022 - 06 - 24
2
2022 - 06 - 08
1
2022 - 06 - 07
2
2022 - 06 - 02
1
2022 - 05 - 31
2
2022 - 05 - 20
3
2022 - 04 - 14
1
2022 - 04 - 07
2
2022 - 04 - 04
2
2022 - 03 - 16
1
2022 - 02 - 28
2
2022 - 02 - 11
1
2022 - 02 - 10
1
2022 - 01 - 31
1
2022 - 01 - 19
2
2022 - 01 - 06
1
2021 - 10 - 22
1
2021 - 10 - 15
1
2021 - 10 - 14
1
2021 - 09 - 29
1
2021 - 09 - 28
1
2021 - 08 - 04
1
2021 - 08 - 03
1
2021 - 07 - 27
1
2021 - 07 - 20
1
2021 - 06 - 26
1
2021 - 06 - 25
4
2021 - 06 - 14
1
2021 - 06 - 11
1
2021 - 06 - 08
1
2021 - 06 - 04
1
2021 - 05 - 24
1
2021 - 04 - 01
1
2021 - 03 - 30
1
2021 - 03 - 18
2
2021 - 03 - 15
1
2021 - 03 - 04
1
2021 - 02 - 25
1
Crawled Time
00:00
1
02:00
4
03:00
1
06:00
18
06:03
1
07:00
10
08:00
5
09:00
3
11:00
7
12:00
17
12:15
1
12:20
6
12:30
1
13:00
16
13:10
1
13:20
5
13:30
1
14:00
4
14:30
1
15:00
2
15:20
1
15:30
1
16:00
1
16:20
1
17:00
4
18:00
4
18:56
1
19:00
3
20:00
4
20:20
2
21:00
6
22:00
4
23:00
7
Source
www.biospace.com
45
www.fda.gov
2
www.globenewswire.com
67
www.prnewswire.com
30
Sort by:
after hours % change
|
delayed % change
|
gain open
|
gain high
|
gain close
|
publishing date
(GMT-12:00) International Date Line West
(GMT-11:00) American Samoa
(GMT-11:00) Midway Island
(GMT-10:00) Hawaii
(GMT-09:00) Alaska
(GMT-08:00) Pacific Time (US & Canada)
(GMT-08:00) Tijuana
(GMT-07:00) Arizona
(GMT-07:00) Chihuahua
(GMT-07:00) Mazatlan
(GMT-07:00) Mountain Time (US & Canada)
(GMT-06:00) Central America
(GMT-06:00) Central Time (US & Canada)
(GMT-06:00) Guadalajara
(GMT-06:00) Mexico City
(GMT-06:00) Monterrey
(GMT-06:00) Saskatchewan
(GMT-05:00) Bogota
(GMT-05:00) Eastern Time (US & Canada)
(GMT-05:00) Indiana (East)
(GMT-05:00) Lima
(GMT-05:00) Quito
(GMT-04:00) Atlantic Time (Canada)
(GMT-04:00) Caracas
(GMT-04:00) Georgetown
(GMT-04:00) La Paz
(GMT-04:00) Puerto Rico
(GMT-04:00) Santiago
(GMT-03:30) Newfoundland
(GMT-03:00) Brasilia
(GMT-03:00) Buenos Aires
(GMT-03:00) Greenland
(GMT-03:00) Montevideo
(GMT-02:00) Mid-Atlantic
(GMT-01:00) Azores
(GMT-01:00) Cape Verde Is.
(GMT+00:00) Casablanca
(GMT+00:00) Dublin
(GMT+00:00) Edinburgh
(GMT+00:00) Lisbon
(GMT+00:00) London
(GMT+00:00) Monrovia
(GMT+00:00) UTC
(GMT+01:00) Amsterdam
(GMT+01:00) Belgrade
(GMT+01:00) Berlin
(GMT+01:00) Bern
(GMT+01:00) Bratislava
(GMT+01:00) Brussels
(GMT+01:00) Budapest
(GMT+01:00) Copenhagen
(GMT+01:00) Ljubljana
(GMT+01:00) Madrid
(GMT+01:00) Paris
(GMT+01:00) Prague
(GMT+01:00) Rome
(GMT+01:00) Sarajevo
(GMT+01:00) Skopje
(GMT+01:00) Stockholm
(GMT+01:00) Vienna
(GMT+01:00) Warsaw
(GMT+01:00) West Central Africa
(GMT+01:00) Zagreb
(GMT+01:00) Zurich
(GMT+02:00) Athens
(GMT+02:00) Bucharest
(GMT+02:00) Cairo
(GMT+02:00) Harare
(GMT+02:00) Helsinki
(GMT+02:00) Jerusalem
(GMT+02:00) Kaliningrad
(GMT+02:00) Kyiv
(GMT+02:00) Pretoria
(GMT+02:00) Riga
(GMT+02:00) Sofia
(GMT+02:00) Tallinn
(GMT+02:00) Vilnius
(GMT+03:00) Baghdad
(GMT+03:00) Istanbul
(GMT+03:00) Kuwait
(GMT+03:00) Minsk
(GMT+03:00) Moscow
(GMT+03:00) Nairobi
(GMT+03:00) Riyadh
(GMT+03:00) St. Petersburg
(GMT+03:30) Tehran
(GMT+04:00) Abu Dhabi
(GMT+04:00) Baku
(GMT+04:00) Muscat
(GMT+04:00) Samara
(GMT+04:00) Tbilisi
(GMT+04:00) Volgograd
(GMT+04:00) Yerevan
(GMT+04:30) Kabul
(GMT+05:00) Ekaterinburg
(GMT+05:00) Islamabad
(GMT+05:00) Karachi
(GMT+05:00) Tashkent
(GMT+05:30) Chennai
(GMT+05:30) Kolkata
(GMT+05:30) Mumbai
(GMT+05:30) New Delhi
(GMT+05:30) Sri Jayawardenepura
(GMT+05:45) Kathmandu
(GMT+06:00) Almaty
(GMT+06:00) Astana
(GMT+06:00) Dhaka
(GMT+06:00) Urumqi
(GMT+06:30) Rangoon
(GMT+07:00) Bangkok
(GMT+07:00) Hanoi
(GMT+07:00) Jakarta
(GMT+07:00) Krasnoyarsk
(GMT+07:00) Novosibirsk
(GMT+08:00) Beijing
(GMT+08:00) Chongqing
(GMT+08:00) Hong Kong
(GMT+08:00) Irkutsk
(GMT+08:00) Kuala Lumpur
(GMT+08:00) Perth
(GMT+08:00) Singapore
(GMT+08:00) Taipei
(GMT+08:00) Ulaanbaatar
(GMT+09:00) Osaka
(GMT+09:00) Sapporo
(GMT+09:00) Seoul
(GMT+09:00) Tokyo
(GMT+09:00) Yakutsk
(GMT+09:30) Adelaide
(GMT+09:30) Darwin
(GMT+10:00) Brisbane
(GMT+10:00) Canberra
(GMT+10:00) Guam
(GMT+10:00) Hobart
(GMT+10:00) Melbourne
(GMT+10:00) Port Moresby
(GMT+10:00) Sydney
(GMT+10:00) Vladivostok
(GMT+11:00) Magadan
(GMT+11:00) New Caledonia
(GMT+11:00) Solomon Is.
(GMT+11:00) Srednekolymsk
(GMT+12:00) Auckland
(GMT+12:00) Fiji
(GMT+12:00) Kamchatka
(GMT+12:00) Marshall Is.
(GMT+12:00) Wellington
(GMT+12:45) Chatham Is.
(GMT+13:00) Nuku'alofa
(GMT+13:00) Samoa
(GMT+13:00) Tokelau Is.
for
symbols :
Regn
save search
SillaJen Submits CSR to the US FDA for REN026 Study in Patients with RCC
Published:
2024-03-27
(Crawled : 23:00)
- biospace.com/
REGN
|
News
|
$906.84
0.74%
0.74%
340K
|
Health Technology
|
-6.58%
|
O:
0.78%
H:
0.4%
C:
-0.49%
ren026
fda
study
Regeneron Provides Update on Biologics License Application for Odronextamab
Published:
2024-03-25
(Crawled : 11:00)
- globenewswire.com
SNYNF
|
News
|
$92.7
-2.18%
600K
|
Health Technology
|
-1.09%
|
O:
-100.0%
H:
NaN%
C:
Infinity%
SNY
|
News
|
$47.69
1.15%
1.13%
1.7M
|
Health Technology
|
-3.73%
|
O:
0.42%
H:
0.0%
C:
0.0%
REGN
|
News
|
$906.84
0.74%
0.74%
340K
|
Health Technology
|
-6.94%
|
O:
-1.37%
H:
1.15%
C:
0.74%
license
update
application
High School Seniors Win $1.8 Million at Regeneron Science Talent Search 2024 for Innovative Scientific Research on Artificial Intelligence, Cancer Metabolism and Mathematical Optimization
Published:
2024-03-13
(Crawled : 02:00)
- globenewswire.com
REGN
|
News
|
$906.84
0.74%
0.74%
340K
|
Health Technology
|
-7.25%
|
O:
0.95%
H:
0.0%
C:
-1.46%
million
cancer
research
Dupixent® (dupilumab) sBLA Accepted for FDA Priority Review for Treatment of COPD with Type 2 Inflammation
Published:
2024-02-23
(Crawled : 06:00)
- globenewswire.com
SNY
|
News
|
$47.69
1.15%
1.13%
1.7M
|
Health Technology
|
-3.42%
|
O:
0.97%
H:
0.0%
C:
0.0%
REGN
|
News
|
$906.84
0.74%
0.74%
340K
|
Health Technology
|
-6.71%
|
O:
1.05%
H:
1.09%
C:
0.64%
dupixent
fda
review
treatment
copd
Press Release: Dupixent® sBLA accepted for FDA Priority Review for treatment of COPD with type 2 inflammation
Published:
2024-02-23
(Crawled : 06:00)
- globenewswire.com
SNY
|
News
|
$47.69
1.15%
1.13%
1.7M
|
Health Technology
|
-3.42%
|
O:
0.97%
H:
0.0%
C:
0.0%
REGN
|
News
|
$906.84
0.74%
0.74%
340K
|
Health Technology
|
-6.71%
|
O:
1.05%
H:
1.09%
C:
0.64%
dupixent
fda
review
treatment
copd
Society for Science Fuels Innovation with $110K in Educator Grants, Transforming Classrooms for Student STEM Research
Published:
2024-02-21
(Crawled : 14:30)
- prnewswire.com
REGN
|
News
|
$906.84
0.74%
0.74%
340K
|
Health Technology
|
-4.93%
|
O:
0.54%
H:
0.63%
C:
0.09%
innovation
research
Linvoseltamab BLA for Treatment of Relapsed/Refractory Multiple Myeloma Accepted for FDA Priority Review
Published:
2024-02-21
(Crawled : 12:00)
- globenewswire.com
SNYNF
|
News
|
$92.7
-2.18%
600K
|
Health Technology
|
-1.49%
|
O:
1.7%
H:
0.0%
C:
0.0%
SNY
|
News
|
$47.69
1.15%
1.13%
1.7M
|
Health Technology
|
-2.37%
|
O:
-0.57%
H:
0.0%
C:
0.0%
REGN
|
News
|
$906.84
0.74%
0.74%
340K
|
Health Technology
|
-4.93%
|
O:
0.54%
H:
0.63%
C:
0.09%
fda
review
treatment
Press Release: Japan first in the world to approve Dupixent® for chronic spontaneous urticaria (CSU)
Published:
2024-02-16
(Crawled : 06:00)
- globenewswire.com
SNYNF
|
News
|
$92.7
-2.18%
600K
|
Health Technology
|
0.42%
|
O:
1.66%
H:
0.0%
C:
-1.59%
SNY
|
News
|
$47.69
1.15%
1.13%
1.7M
|
Health Technology
|
-0.51%
|
O:
-0.6%
H:
0.0%
C:
0.0%
REGN
|
News
|
$906.84
0.74%
0.74%
340K
|
Health Technology
|
-5.72%
|
O:
-0.14%
H:
0.32%
C:
-0.57%
dupixent
first
japan
urticaria
world
Japan First in the World to Approve Dupixent® (dupilumab) for Chronic Spontaneous Urticaria (CSU)
Published:
2024-02-16
(Crawled : 06:00)
- globenewswire.com
SNYNF
|
News
|
$92.7
-2.18%
600K
|
Health Technology
|
0.42%
|
O:
1.66%
H:
0.0%
C:
-1.59%
SNY
|
News
|
$47.69
1.15%
1.13%
1.7M
|
Health Technology
|
-0.51%
|
O:
-0.6%
H:
0.0%
C:
0.0%
REGN
|
News
|
$906.84
0.74%
0.74%
340K
|
Health Technology
|
-5.72%
|
O:
-0.14%
H:
0.32%
C:
-0.57%
dupixent
first
japan
urticaria
world
Linvoseltamab Receives EMA Filing Acceptance for Treatment of Relapsed/Refractory Multiple Myeloma
Published:
2024-02-02
(Crawled : 11:00)
- globenewswire.com
SNY
|
News
|
$47.69
1.15%
1.13%
1.7M
|
Health Technology
|
-4.51%
|
O:
-0.93%
H:
0.0%
C:
0.0%
REGN
|
News
|
$906.84
0.74%
0.74%
340K
|
Health Technology
|
-6.02%
|
O:
1.4%
H:
0.28%
C:
-2.68%
treatment
ema
Dupixent® (dupilumab) FDA Approved as First and Only Treatment Indicated for Children Aged 1 Year and Older with Eosinophilic Esophagitis (EoE)
Published:
2024-01-25
(Crawled : 20:00)
- globenewswire.com
SNYNF
|
News
|
$92.7
-2.18%
600K
|
Health Technology
|
-6.6%
|
O:
1.8%
H:
0.0%
C:
-1.82%
SNY
|
News
|
$47.69
1.15%
1.13%
1.7M
|
Health Technology
|
-7.26%
|
O:
0.5%
H:
0.0%
C:
0.0%
REGN
|
News
|
$906.84
0.74%
0.74%
340K
|
Health Technology
|
-5.13%
|
O:
0.33%
H:
0.65%
C:
-1.26%
dupixent
fda
first
children
approved
year
treatment
Press Release: Dupixent® FDA approved as first and only treatment indicated for children aged 1 year and older with eosinophilic esophagitis (EoE)
Published:
2024-01-25
(Crawled : 20:00)
- globenewswire.com
SNYNF
|
News
|
$92.7
-2.18%
600K
|
Health Technology
|
-6.6%
|
O:
1.8%
H:
0.0%
C:
-1.82%
SNY
|
News
|
$47.69
1.15%
1.13%
1.7M
|
Health Technology
|
-7.26%
|
O:
0.5%
H:
0.0%
C:
0.0%
REGN
|
News
|
$906.84
0.74%
0.74%
340K
|
Health Technology
|
-5.13%
|
O:
0.33%
H:
0.65%
C:
-1.26%
dupixent
fda
first
children
approved
year
treatment
Top 40 High School Scientists in Prestigious Regeneron Science Talent Search to Compete for $1.8 Million in Awards
Published:
2024-01-24
(Crawled : 17:00)
- globenewswire.com
REGN
|
News
|
$906.84
0.74%
0.74%
340K
|
Health Technology
|
-5.7%
|
O:
0.26%
H:
0.0%
C:
-0.92%
million
awards
Ultragenyx Receives Positive Recommendation from NICE in the U.K. for Evkeeza® ▼ (evinacumab) for Adolescents and Adults Aged 12 Years and Older with Homozygous Familial Hypercholesterolemia (HoFH)
Published:
2024-01-04
(Crawled : 13:00)
- globenewswire.com
RARE
F
|
$45.06
3.14%
3.04%
840K
|
Health Technology
|
-8.88%
|
O:
0.83%
H:
1.57%
C:
-2.61%
REGN
|
News
|
$906.84
0.74%
0.74%
340K
|
Health Technology
|
-1.9%
|
O:
0.02%
H:
0.77%
C:
-0.61%
evkeeza
positive
hypercholesterolemia
Biologics Global Market Forecast Report 2024-2034 - Challenges Posed by Patent Expiration for Biologics
Published:
2023-12-22
(Crawled : 17:00)
- prnewswire.com
SNYNF
|
News
|
$92.7
-2.18%
600K
|
Health Technology
|
-3.25%
|
O:
3.66%
H:
0.0%
C:
-0.12%
AZNCF
|
News
|
$138.73
-4.19%
3.7K
|
Health Technology
|
6.31%
|
O:
3.33%
H:
0.0%
C:
-2.93%
NVO
|
News
|
$128.64
2.7%
-0.07%
3.7M
|
Health Technology
|
21.05%
|
O:
-0.31%
H:
0.39%
C:
-0.44%
JNJ
|
News
|
$149.56
0.3%
0.0%
9.1M
|
Health Technology
|
-2.87%
|
O:
1.09%
H:
0.0%
C:
0.0%
LLY
|
News
|
$745.69
1.96%
-0.16%
2M
|
Health Technology
|
27.85%
|
O:
0.18%
H:
0.5%
C:
-0.46%
BMY
|
$48.99
-0.31%
0.0%
9.1M
|
Health Technology
|
-4.14%
|
O:
-0.78%
H:
5.15%
C:
2.81%
ABBV
|
News
|
$169.54
0.98%
-0.91%
4.1M
|
Health Technology
|
10.03%
|
O:
0.58%
H:
0.0%
C:
0.0%
SNY
|
News
|
$47.69
1.15%
1.13%
1.7M
|
Health Technology
|
-5.04%
|
O:
1.03%
H:
0.0%
C:
0.0%
REGN
|
News
|
$906.84
0.74%
0.74%
340K
|
Health Technology
|
6.92%
|
O:
0.52%
H:
0.58%
C:
0.05%
GILD
|
$67.03
0.12%
0.12%
5.2M
|
Health Technology
|
-15.18%
|
O:
0.34%
H:
1.02%
C:
0.59%
BIIB
|
$193.18
-0.48%
-0.48%
1.4M
|
Health Technology
|
-23.54%
|
O:
0.57%
H:
1.36%
C:
1.04%
AZN
|
News
|
$70.85
1.03%
1.02%
5.6M
|
Health Technology
|
5.78%
|
O:
1.06%
H:
0.18%
C:
-1.06%
AMGN
|
News
|
$273.69
0.66%
0.65%
2.5M
|
Health Technology
|
-2.66%
|
O:
0.24%
H:
2.03%
C:
1.49%
patent
report
global
market
Ultragenyx Receives European Commission Decision for Evkeeza® (evinacumab) Expanded Indication in Children Aged 5 Years and Older with Homozygous Familial Hypercholesterolemia (HoFH)
Published:
2023-12-18
(Crawled : 13:00)
- globenewswire.com
RARE
F
|
$45.06
3.14%
3.04%
840K
|
Health Technology
|
-4.96%
|
O:
-0.07%
H:
1.61%
C:
-0.61%
REGN
|
News
|
$906.84
0.74%
0.74%
340K
|
Health Technology
|
4.77%
|
O:
-0.62%
H:
0.48%
C:
-0.34%
evkeeza
children
hypercholesterolemia
Regeneron Named on Dow Jones Sustainability World Index for Fifth Consecutive Year
Published:
2023-12-11
(Crawled : 12:30)
- globenewswire.com
REGN
|
News
|
$906.84
0.74%
0.74%
340K
|
Health Technology
|
7.14%
|
O:
-0.2%
H:
1.35%
C:
1.19%
index
jones
year
world
Dupixent® (dupilumab) Significantly Reduced COPD Exacerbations in Second Positive Phase 3 Trial, Accelerating FDA Submission and Confirming Potential to Become First Approved Biologic for This Serious Disease
Published:
2023-11-27
(Crawled : 07:00)
- globenewswire.com
SNYNF
|
News
|
$92.7
-2.18%
600K
|
Health Technology
|
-2.62%
|
O:
-0.36%
H:
0.0%
C:
0.0%
SNY
|
News
|
$47.69
1.15%
1.13%
1.7M
|
Health Technology
|
-1.77%
|
O:
1.04%
H:
0.17%
C:
0.11%
REGN
|
News
|
$906.84
0.74%
0.74%
340K
|
Health Technology
|
12.76%
|
O:
0.46%
H:
0.37%
C:
-0.49%
dupixent
fda
disease
approved
positive
copd
potential
submission
Press Release: Dupixent® significantly reduced COPD exacerbations in second positive Phase 3 trial, accelerating FDA submission and confirming potential to become first approved biologic for this serious disease
Published:
2023-11-27
(Crawled : 07:00)
- globenewswire.com
SNYNF
|
News
|
$92.7
-2.18%
600K
|
Health Technology
|
-2.62%
|
O:
-0.36%
H:
0.0%
C:
0.0%
SNY
|
News
|
$47.69
1.15%
1.13%
1.7M
|
Health Technology
|
-1.77%
|
O:
1.04%
H:
0.17%
C:
0.11%
REGN
|
News
|
$906.84
0.74%
0.74%
340K
|
Health Technology
|
12.76%
|
O:
0.46%
H:
0.37%
C:
-0.49%
dupixent
fda
disease
approved
positive
copd
potential
submission
Dupixent® (dupilumab) Phase 3 Results Show Sustained Efficacy for Up to One Year in Children 1 to 11 Years of Age with Eosinophilic Esophagitis (EoE)
Published:
2023-10-22
(Crawled : 20:20)
- globenewswire.com
SNYNF
|
News
|
$92.7
-2.18%
600K
|
Health Technology
|
-10.22%
|
O:
0.73%
H:
0.0%
C:
-0.48%
SNY
|
News
|
$47.69
1.15%
1.13%
1.7M
|
Health Technology
|
-11.6%
|
O:
-0.69%
H:
0.0%
C:
0.0%
REGN
|
News
|
$906.84
0.74%
0.74%
340K
|
Health Technology
|
11.34%
|
O:
0.21%
H:
0.08%
C:
-1.81%
dupixent
children
year
one
results
show
← Previous
1
2
3
4
5
6
7
8
Next →
Gainers vs Losers
78%
22%
Top 10 Gainers
MTTR
|
News
4
|
$4.6
164.37%
62.17%
28M
|
AGBA
|
$2.94
135.2%
57.48%
66M
|
Finance
EDBL
|
News
|
$6.46
71.81%
41.8%
2M
|
MTC
|
$2.25
44.23%
30.67%
6M
|
Technology Services
OPRT
|
News
|
$3.175
41.11%
29.13%
12M
|
Finance
SHIM
|
$3.05
35.56%
26.23%
1.1M
|
HKIT
|
$1.345
31.86%
24.16%
390K
|
Technology Services
ABVC
|
$1.36
30.77%
23.53%
7.4M
|
Wholesale Trade
OST
|
$0.512
28.0%
21.88%
290K
|
POET
|
$1.59
27.2%
21.38%
4.2M
|
Manufacturing
Your saved searches
Save your searches and get alerts when important news are released.